Insider Selling: Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Director Sells 500 Shares of Stock

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Get Free Report) Director Floyd F. Petersen sold 500 shares of the firm's stock in a transaction that occurred on Tuesday, April 1st. The shares were sold at an average price of $28.38, for a total transaction of $14,190.00. Following the completion of the sale, the director now owns 73,909 shares of the company's stock, valued at approximately $2,097,537.42. This trade represents a 0.67 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Amphastar Pharmaceuticals Stock Performance

AMPH stock traded down $1.61 during midday trading on Monday, reaching $25.00. The stock had a trading volume of 1,290,482 shares, compared to its average volume of 448,842. The firm has a fifty day simple moving average of $29.99 and a two-hundred day simple moving average of $39.00. Amphastar Pharmaceuticals, Inc. has a 52-week low of $24.74 and a 52-week high of $53.96. The company has a debt-to-equity ratio of 0.82, a quick ratio of 2.61 and a current ratio of 3.43. The stock has a market cap of $1.19 billion, a PE ratio of 8.33, a P/E/G ratio of 2.19 and a beta of 0.79.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. Smartleaf Asset Management LLC increased its holdings in Amphastar Pharmaceuticals by 222.1% in the 4th quarter. Smartleaf Asset Management LLC now owns 715 shares of the company's stock worth $26,000 after buying an additional 493 shares during the period. Parkside Financial Bank & Trust increased its stake in shares of Amphastar Pharmaceuticals by 806.5% in the fourth quarter. Parkside Financial Bank & Trust now owns 979 shares of the company's stock worth $36,000 after acquiring an additional 871 shares during the period. GF Fund Management CO. LTD. acquired a new stake in shares of Amphastar Pharmaceuticals in the fourth quarter worth $38,000. Tower Research Capital LLC TRC raised its holdings in shares of Amphastar Pharmaceuticals by 43.7% during the fourth quarter. Tower Research Capital LLC TRC now owns 1,145 shares of the company's stock worth $43,000 after purchasing an additional 348 shares during the last quarter. Finally, Huntington National Bank lifted its position in Amphastar Pharmaceuticals by 36.9% during the fourth quarter. Huntington National Bank now owns 1,340 shares of the company's stock valued at $50,000 after purchasing an additional 361 shares during the period. 65.09% of the stock is currently owned by hedge funds and other institutional investors.

Remove Ads

Analyst Upgrades and Downgrades

Separately, Piper Sandler decreased their price objective on shares of Amphastar Pharmaceuticals from $36.00 to $32.00 and set a "neutral" rating for the company in a research report on Friday, March 21st.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.